Close Menu

Biodesix

By Tony Fong
NEW YORK (GenomeWeb News) – Biodesix is progressing on its plans to partner with pharmaceutical and biotechnology firms to drive adoption of its VeriStrat test, a company official told GenomeWeb Daily News last week.

This story originally ran on Dec. 13.
Biodesix last week presented results from a retrospective analysis of breast cancer patients using its serum proteomic Veristrat diagnostic.

A study published this month in the Journal of Thoracic Oncology supports the usefulness of Biodesix's VeriStrat lung cancer diagnostic in monitori

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Biodesix today announced two partnerships to increase patient access to its VeriStrat molecular diagnostic test for non-small cell lung cancer.

In particular, the study indicates that the technology's limit of detection is not yet sufficient to detect key low-abundance proteins and that it suffers from reproducibility issues that, while ultimately resolvable, could present significant practical obstacles in a clinical environment.

The funds will go toward commercialization of its VeriStrat test for non-small cell lung cancer and to support collaborations with biotechnology and pharmaceutical firms to develop companion diagnostics.

According to a document filed with the SEC, Biodesix has raised half of its goal of $20 million. Funds will be used to further commercialize its VeriStrat test.

EGFR has emerged as a primary area of interest in cancer research, with biopharmaceuticals like Imclone's Erbitux and Amgen's Vectibix targeting the protein, but its multiple isoforms have made it difficult to predict these drugs' effectiveness, said Yale professor Nita Maihle.

The patents cover the selection of non-small cell lung cancer patients, colorectal cancer patients, and head and neck cancer patients for treatment with drugs targeting the epidermal growth-factor receptor pathway.

Veristrat, a protein biomarker-based companion diagnostic for non-small cell lung cancer, launched commercially in May 2009.

Pages

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.

A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.

In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.